vs
Side-by-side financial comparison of FARMERS NATIONAL BANC CORP (FMNB) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $71.5M, roughly 1.3× FARMERS NATIONAL BANC CORP). Vericel Corp runs the higher net margin — 25.0% vs 20.5%, a 4.5% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 3.2%). FARMERS NATIONAL BANC CORP produced more free cash flow last quarter ($52.2M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 6.2%).
Farmers National Banc Corp (OH) is a regional financial holding company based in Ohio, the United States. It offers full-spectrum retail and commercial banking products, wealth management solutions, and insurance services, primarily catering to individual consumers, small and medium-sized enterprises, and local community clients in Ohio and adjacent Midwestern U.S. regions.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
FMNB vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $71.5M | $92.9M |
| Net Profit | $14.6M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | 24.8% | 24.1% |
| Net Margin | 20.5% | 25.0% |
| Revenue YoY | 3.2% | 23.3% |
| Net Profit YoY | 1.7% | 17.3% |
| EPS (diluted) | $0.39 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.5M | $92.9M | ||
| Q3 25 | $70.8M | $67.5M | ||
| Q2 25 | $69.8M | $63.2M | ||
| Q1 25 | $67.8M | $52.6M | ||
| Q4 24 | $69.3M | $75.4M | ||
| Q3 24 | $70.3M | $57.9M | ||
| Q2 24 | $66.5M | $52.7M | ||
| Q1 24 | $63.4M | $51.3M |
| Q4 25 | $14.6M | $23.2M | ||
| Q3 25 | $12.5M | $5.1M | ||
| Q2 25 | $13.9M | $-553.0K | ||
| Q1 25 | $13.6M | $-11.2M | ||
| Q4 24 | $14.4M | $19.8M | ||
| Q3 24 | $8.5M | $-901.0K | ||
| Q2 24 | $11.8M | $-4.7M | ||
| Q1 24 | $11.2M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | 24.8% | 24.1% | ||
| Q3 25 | 20.7% | 5.1% | ||
| Q2 25 | 23.4% | -3.2% | ||
| Q1 25 | 24.1% | -24.3% | ||
| Q4 24 | 25.5% | 24.5% | ||
| Q3 24 | 14.4% | -4.3% | ||
| Q2 24 | 21.3% | -11.5% | ||
| Q1 24 | 21.2% | -10.7% |
| Q4 25 | 20.5% | 25.0% | ||
| Q3 25 | 17.6% | 7.5% | ||
| Q2 25 | 19.9% | -0.9% | ||
| Q1 25 | 20.0% | -21.4% | ||
| Q4 24 | 20.8% | 26.3% | ||
| Q3 24 | 12.1% | -1.6% | ||
| Q2 24 | 17.7% | -8.9% | ||
| Q1 24 | 17.7% | -7.5% |
| Q4 25 | $0.39 | $0.46 | ||
| Q3 25 | $0.33 | $0.10 | ||
| Q2 25 | $0.37 | $-0.01 | ||
| Q1 25 | $0.36 | $-0.23 | ||
| Q4 24 | $0.38 | $0.40 | ||
| Q3 24 | $0.23 | $-0.02 | ||
| Q2 24 | $0.31 | $-0.10 | ||
| Q1 24 | $0.30 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | $86.7M | — |
| Stockholders' EquityBook value | $485.7M | $354.6M |
| Total Assets | $5.2B | $488.0M |
| Debt / EquityLower = less leverage | 0.18× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M | ||
| Q1 24 | — | $110.6M |
| Q4 25 | $86.7M | — | ||
| Q3 25 | $86.6M | — | ||
| Q2 25 | $86.4M | — | ||
| Q1 25 | $86.3M | — | ||
| Q4 24 | $86.2M | — | ||
| Q3 24 | $86.0M | — | ||
| Q2 24 | $88.9M | — | ||
| Q1 24 | $88.8M | — |
| Q4 25 | $485.7M | $354.6M | ||
| Q3 25 | $465.9M | $321.9M | ||
| Q2 25 | $437.7M | $306.8M | ||
| Q1 25 | $429.1M | $295.5M | ||
| Q4 24 | $406.0M | $292.0M | ||
| Q3 24 | $439.7M | $257.5M | ||
| Q2 24 | $396.7M | $243.0M | ||
| Q1 24 | $397.0M | $233.9M |
| Q4 25 | $5.2B | $488.0M | ||
| Q3 25 | $5.2B | $453.3M | ||
| Q2 25 | $5.2B | $435.6M | ||
| Q1 25 | $5.2B | $424.6M | ||
| Q4 24 | $5.1B | $432.7M | ||
| Q3 24 | $5.2B | $390.4M | ||
| Q2 24 | $5.2B | $376.8M | ||
| Q1 24 | $5.1B | $356.7M |
| Q4 25 | 0.18× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.20× | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 0.20× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.22× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.0M | $15.0M |
| Free Cash FlowOCF − Capex | $52.2M | $12.8M |
| FCF MarginFCF / Revenue | 73.0% | 13.8% |
| Capex IntensityCapex / Revenue | 11.0% | 2.4% |
| Cash ConversionOCF / Net Profit | 4.10× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $85.8M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.0M | $15.0M | ||
| Q3 25 | $10.7M | $22.1M | ||
| Q2 25 | $14.0M | $8.2M | ||
| Q1 25 | $15.7M | $6.6M | ||
| Q4 24 | $66.6M | $22.2M | ||
| Q3 24 | $23.9M | $10.2M | ||
| Q2 24 | $16.6M | $18.5M | ||
| Q1 24 | $13.7M | $7.2M |
| Q4 25 | $52.2M | $12.8M | ||
| Q3 25 | $9.0M | $19.5M | ||
| Q2 25 | $12.4M | $81.0K | ||
| Q1 25 | $12.2M | $-7.6M | ||
| Q4 24 | $54.9M | $8.5M | ||
| Q3 24 | $20.4M | $-9.2M | ||
| Q2 24 | $14.4M | $1.8M | ||
| Q1 24 | $12.2M | $-6.8M |
| Q4 25 | 73.0% | 13.8% | ||
| Q3 25 | 12.8% | 28.8% | ||
| Q2 25 | 17.8% | 0.1% | ||
| Q1 25 | 18.0% | -14.5% | ||
| Q4 24 | 79.2% | 11.2% | ||
| Q3 24 | 29.1% | -15.9% | ||
| Q2 24 | 21.6% | 3.4% | ||
| Q1 24 | 19.2% | -13.3% |
| Q4 25 | 11.0% | 2.4% | ||
| Q3 25 | 2.4% | 3.9% | ||
| Q2 25 | 2.3% | 12.9% | ||
| Q1 25 | 5.2% | 27.0% | ||
| Q4 24 | 16.9% | 18.3% | ||
| Q3 24 | 4.9% | 33.5% | ||
| Q2 24 | 3.3% | 31.8% | ||
| Q1 24 | 2.4% | 27.3% |
| Q4 25 | 4.10× | 0.65× | ||
| Q3 25 | 0.86× | 4.35× | ||
| Q2 25 | 1.01× | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 4.63× | 1.12× | ||
| Q3 24 | 2.80× | — | ||
| Q2 24 | 1.41× | — | ||
| Q1 24 | 1.22× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FMNB
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
